Europos Sąjunga -
lietuvių -
EMA (European Medicines Agency)
tecvayli
janssen-cilag international n.v. - teclistamab - daugybinė mieloma - antinavikiniai vaistai - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.
Europos Sąjunga -
lietuvių -
EMA (European Medicines Agency)
sugammadex amomed
aop orphan pharmaceuticals gmbh - sugammadex sodium - neuromuskulinė blokada - visi kiti gydomieji produktai - rukuronio arba vekuronio sukeltos nervų ir raumenų blokados pasikeitimas. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
Europos Sąjunga -
lietuvių -
EMA (European Medicines Agency)
akeega
janssen-cilag international n.v. - abiraterone acetate, niraparib tosilate monohydrate - prostatos navikai, kastracija-atsparus - antinavikiniai vaistai - treatment of adult patients with prostate cancer.
Europos Sąjunga -
lietuvių -
EMA (European Medicines Agency)
bekemv
amgen technology (ireland) uc - eculizumab - hemoglobinurija, paroksizminis - imunosupresantai - bekemv is indicated in adults and children for the treatment of paroxysmal nocturnal haemoglobinuria (pnh). Įrodymų, kad klinikinė nauda yra įrodyta, pacientams, sergantiems haemolysis su klinikinis simptomas(s) rodo aukštą ligos aktyvumo, nepriklausomai nuo perpylimo istorija (žr. skyrių 5.
Europos Sąjunga -
lietuvių -
EMA (European Medicines Agency)
talvey
janssen-cilag international n.v. - talquetamab - daugybinė mieloma - antinavikiniai vaistai - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.